Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,685.43
+29.831.12%
Number of Gainers:57
Number of Losers:39
Number of Flat:2
PE:- -
High:2,697.11
Open:2,655.45
Low:2,655.45
Close:2,655.60
Volume:1.18B
Turnover:239.15B
Market Cap:49.12T
Float Cap:45.71T

Loading ...

CScale Raises $145 Million for AI Networking, with Backing from Nvidia and Intel

Reuters
·
Sep 30

Illinois Tool Works named short-term sell idea at Deutsche Bank

TIPRANKS
·
Sep 30

What the History of Electric Wires Can Teach Us About the Data Center Backlash

InvestorPlace
·
Sep 30

Premarket: Nasdaq Futures Slip 0.09% as Investors Await Micron Earnings

Deep News
·
Sep 30

Breaking: Jensen Huang Set to Take On Role at Tsinghua University

Deep News
·
Sep 30

Trane announces demonstration of 800-volt direct current chiller

TIPRANKS
·
Sep 30

Silo Pharma Unit QwikAgents Adds Nvidia Nemotron Model Support

Reuters
·
Sep 30

Silo Pharma’s Qwikagents Expands AI Agent Platform with Nvidia Model Support and New Runtime Flexibility

THOMSON REUTERS
·
Sep 30

Cummins Inc : UBS Cuts Target Price to $741 from $835

THOMSON REUTERS
·
Sep 30

AIxCrypto to change name to FF EAI Robotics Ecosystem

TIPRANKS
·
Sep 30

UBS Sticks to Its Hold Rating for Apple (AAPL)

TIPRANKS
·
Sep 30

Tesla's Cash Crunch Has Arrived-Blame Its AI Ambitions

Dow Jones
·
Sep 30

Skyworks Secures Regulatory Clearances for Qorvo Deal, Targets Oct. 5 Close

Reuters
·
Sep 30

Qorvo - Skyworks and Qorvo Expect to Close Mergers on or About October 5, 2026

THOMSON REUTERS
·
Sep 30

Press Release: Skyworks Receives All Necessary Clearances for Proposed Combination with Qorvo

Dow Jones
·
Sep 30

Micron Faces Earnings Test Tonight After 40% Stock Rebound: Net Income Expected to Surge Over 1000%, Market Focuses on Next Year's AI Capital Expenditure

Deep News
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30